GW Pharmaceuticals Appoints Stephen D. Schultz as Vice President of Investor Relations
Published: Mar 19, 2013
Mr. Schultz has close to 25 years of experience in investor relations, financial communications and media relations. Most recently, Mr. Schultz served as Senior Director of Investor Relations and Corporate Communications at Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. At Amarin, Mr. Schultz led the company’s investor program from Phase 3 clinical trials of its lead product Vascepa® through approval from the U.S. Food and Drug Administration in 2012 and U.S. commercial launch in January 2013.
Prior to Amarin, Mr. Schultz served as the Executive Director of the Jackson Hole Center for the Arts, a not-for-profit organization aimed at promoting artistic creativity and education. Mr. Schultz’s extensive investor relations and corporate communications experience also includes senior-level roles at Acusphere, Shareholder.com (a Nasdaq company), Manufacturer’s Services Limited, Wang Global and The ForeFront Group. Mr. Schultz holds a B.A. degree from St. Lawrence University.
Justin Gover, GW’s Chief Executive Officer, said, "We are pleased to welcome Steve to the GW team. Steve’s extensive investor relations expertise in the U.S. is intended to provide us with an important new resource as we prepare for a future which is increasingly focused on the U.S. market”.
Mr. Schultz said, "I am excited to be joining GW at this stage in the Company’s development. I look forward to working with the GW team to support and build the Company’s investor relations efforts in the U.S."
GW Pharmaceuticals plc (Today) +44 20 7831 3113
Justin Gover, Chief Executive Officer (Thereafter) +44 1980 557000
Stephen Schultz, VP Investor Relations +1 401 500 6570
Trout Group LLC +1 646 378 2900
FTI Consulting +44 20 7831 3113
Ben Atwell / Simon Conway / John Dineen
Founded in 1998, GW is biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 20 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter clinical trials in the next 12 months.
For further information, please visit www.gwpharm.com